FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer
Crossref DOI link: https://doi.org/10.1007/s00280-017-3319-4
Published Online: 2017-05-10
Published Print: 2017-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Xu, Y. L. http://orcid.org/0000-0002-6534-9647
Yao, R.
Li, J.
Zhou, Y. D.
Mao, F.
Pan, B.
Sun, Q.
Funding for this research was provided by:
Beijing Municipal Natural Science Foundation (7164292)
National Natural Science Foundation of China (CN) (81001183)
License valid from 2017-05-10